Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Moderna (MRNA) stock in plain English

Free brief · no signupStart here
MRNAPublished Nov 18, 2026
Moderna Inc
Healthcare · Biotechnology
Produces mRNA-based vaccines targeting viral diseases, including respiratory syncytial virus and COVID-19.
Assets:
Norwood technology center650,000-square-foot Massachusetts facility handling clinical and commercial production
Approved product portfolioCommercial mRNA vaccines covering COVID-19 and respiratory syncytial virus
Development pipelineOver 40 active clinical programs targeting infectious diseases and cancer
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
+1.29%$199.33
$80.65B
n/a (loss)
$2.53B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MRNA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Moderna (MRNA) do?

Moderna Inc (MRNA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Produces mRNA-based vaccines targeting viral diseases, including respiratory syncytial virus and COVID-19. Operates a messenger RNA platform that quickly programs biological cells to produce specific therapeutic proteins. It is worth $80.65B on the market and sold $2.53B over the last year.

Market cap
$80.65B
P/E ratio
None (reported a loss)
Annual sales
$2.53B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind MRNA

  • Spikevax: Sells an mRNA vaccine protecting against COVID-19 to governments and commercial pharmacies globally.
  • mRESVIA: Provides an mRNA vaccine protecting older adults against respiratory syncytial virus through healthcare provider distribution.

MRNA’s flags, in plain English

Each flag is a number from Moderna’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 19.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Insiders Hold

Insiders own 8.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -110.5%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about MRNA

How big is Moderna?

Moderna’s market cap is $80.65B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.53B: what customers paid the company over the last year, before any costs.

What is MRNA’s P/E ratio?

MRNA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with MRNA?

The business generates net losses as global demand for its COVID-19 vaccine continues to drop sharply. That is one risk on Moderna’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Moderna’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRNA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card